Guardant Health delivered total revenue of $301.7 million for Q1 2026, marking a 48% increase from the prior year period. Oncology segment revenue reached $205.0 million, up 36%, supported by approximately 86,000 tests processed, a 47% volume gain.

Reflecting the stronger-than-expected first-quarter results and sustained test volume acceleration, the company raised its full-year 2026 revenue guidance, underscoring confidence in ongoing market adoption of its precision oncology offerings.